Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

China Pharma Holdings (CPHI) Long-Term Debt Issuances (2016 - 2025)

China Pharma Holdings' Long-Term Debt Issuances history spans 14 years, with the latest figure at $7573.0 for Q4 2025.

  • For Q4 2025, Long-Term Debt Issuances rose 11.33% year-over-year to $7573.0; the TTM value through Dec 2025 reached $261070.0, up 854.45%, while the annual FY2025 figure was $261070.0, 854.45% up from the prior year.
  • Long-Term Debt Issuances reached $7573.0 in Q4 2025 per CPHI's latest filing, up from -$44176.0 in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $626188.0 in Q2 2021 to a low of -$47241.0 in Q1 2022.
  • Average Long-Term Debt Issuances over 5 years is $84158.7, with a median of $7018.0 recorded in 2022.
  • The largest YoY upside for Long-Term Debt Issuances was 4145.27% in 2025 against a maximum downside of 745.56% in 2025.
  • A 5-year view of Long-Term Debt Issuances shows it stood at $11170.0 in 2021, then tumbled by 38.69% to $6848.0 in 2022, then grew by 1.42% to $6945.0 in 2023, then dropped by 2.06% to $6802.0 in 2024, then grew by 11.33% to $7573.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Long-Term Debt Issuances are $7573.0 (Q4 2025), -$44176.0 (Q3 2025), and $290886.0 (Q2 2025).